Business Context and Reporting Period
Company: Clarivate Plc
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2026
Business Overview: Clarivate is a global provider of intelligence solutions, workflow solutions, and tech-enabled services across three segments: Academia & Government (A&G), Intellectual Property (IP), and Life Sciences & Healthcare (LS&H). The company operates as a large accelerated filer.
Key Financial Metrics
| Metric | Q2 2026 | Q2 2025 | YTD 2026 | YTD 2025 |
|---|---|---|---|---|
| Revenues | $587.3M | $621.4M | $1,172.8M | $1,215.1M |
| Net Income (Loss) | $(268.6M) | $(72.0M) | $(308.8M) | $(175.9M) |
| Adjusted EBITDA | $247.2M | $261.6M | $488.4M | $494.8M |
| Adjusted EBITDA Margin | 42.1% | 42.1% | 41.6% | 40.7% |
| Operating Cash Flow (YTD) | $233.4M | $287.5M | - | - |
| Free Cash Flow (YTD) | $122.9M | $160.6M | - | - |
| Total Debt Outstanding | $4,251.5M | - | - | - |
| Cash & Equivalents | $217.7M | - | - | - |
Note: Debt and Cash figures represent balances as of June 30, 2026.
Material Changes vs. Prior Period
- Revenue Decline: Revenues decreased 5.5% QoQ and 3.5% YTD, driven primarily by product group wind-downs in the LS&H and A&G segments and lower transactional activity. Organic revenue growth was flat to slightly negative (-1.5% QoQ, -0.4% YTD).
- Significant Impairment Charge: The company recorded a non-cash goodwill impairment charge of $221.7M in Q2 2026 related to the LS&H reporting unit. This charge was triggered by the identification of strategic alternatives and the anticipated sale price of the business.
- Net Loss Expansion: Net loss widened significantly to $(268.6M) for Q2 2026 compared to $(72.0M) in Q2 2025, largely due to the impairment charge and restructuring costs.
- Debt Reduction: Total debt decreased from $4,469.9M at year-end 2025 to $4,251.5M in Q2 2026. The company redeemed $100M of Senior Secured Notes in January 2026 and repurchased additional debt totaling $111.1M during the six-month period.
- Restructuring: Restructuring costs totaled $12.1M for Q2 2026, associated with the ongoing "Value Creation Plan."
Guidance, Outlook, and Risks
- Strategic Divestiture: In July 2026 (subsequent to the reporting period), Clarivate entered a definitive agreement to sell its LS&H business to an affiliate of Altaris LLC for an aggregate purchase price of $600.0M ($500M cash, $25M deferred, $75M seller note). The transaction is expected to close by year-end 2026, and the LS&H segment will be reported as a discontinued operation starting Q3 2026.
- Capital Allocation: The company expects proceeds from the LS&H sale to strengthen the balance sheet through debt reduction. A share repurchase program remains active with $257.4M of availability remaining through December 31, 2026.
- Key Risks:
- Execution risk regarding the divestiture of the LS&H business and regulatory approvals.
- Dependence on third-party data sources and competition from free information sources.
- Cybersecurity threats and data privacy regulations.
- Exposure to foreign exchange fluctuations and interest rate volatility.
- Ongoing securities class action litigation regarding prior accounting errors and disclosures.
Investor Verification Checklist
- Divestiture Terms: Verify the closing conditions and timeline for the $600M sale of the LS&H business to Altaris LLC.
- Impairment Rationale: Confirm the fair value assessment methodology used for the $221.7M goodwill impairment and its impact on future tax provisions.
- Debt Structure: Review the maturity profile of the remaining $4.25B debt and the impact of the recent debt repurchases on interest expense.
- Legal Proceedings: Monitor the status of the securities class action lawsuits filed in 2022 regarding internal controls and financial reporting.
- Organic Growth: Assess the sustainability of organic revenue growth in the A&G and IP segments following the wind-down of specific product groups.